title: Genetically Engineered Multivalent Proteins for Targeted Immunotherapy.
abstract: mAbs initiated the unprecedented breakthroughs in cancer immunotherapy and are rapidly evolving with multiple therapeutic platforms. One next-generation strategy engineers multivalent proteins that ligate single-chain variable fragments targeting cellular effectors, tumor-associated antigens, and cytokines. These developing therapeutics target and regulate cellular effector bioactivity and significantly improve clinical outcomes. Clin Cancer Res; 22(14); 3419-21. ©2016 AACRSee related article by Vallera et al., p. 3440.
authors.affiliation: University of Nebraska Medical Center, Omaha, Nebraska. jtalmadg@unmc.edu.
authors.forename: James E
authors.initials: JE
authors.lastname: Talmadge
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use; D000951:Antigens, Neoplasm / Q000276:immunology; D045744:Cell Line, Tumor; D016207:Cytokines / Q000276:immunology; D018922:HL-60 Cells; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007694:Killer Cells, Natural; D051379:Mice; D009369:Neoplasms / Q000628:therapy*; D011506:Proteins / Q000235:genetics* / Q000276:immunology / Q000627:therapeutic use*; D057127:Single-Chain Antibodies / Q000235:genetics / Q000276:immunology / Q000627:therapeutic use
chemical_list: D000911:Antibodies, Monoclonal; D000951:Antigens, Neoplasm; D016207:Cytokines; D011506:Proteins; D057127:Single-Chain Antibodies